{"id":"W4220929644","doi":"10.1016/j.ejca.2022.02.009","title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Tolerability; Internal medicine; Adverse effect; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Discontinuation; Gastroenterology; Progression-free survival; Surgery; Oncology; Phases of clinical research; Toxicity; Clinical trial; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001645865,0.0006540577,0.001825184,0.000398051,0.0002751755,0.00112604,0.0005665648,0.0005748456,0.002504159],"category_scores_gemma":[0.00127261,0.0004449942,0.001647596,0.0004296193,0.0004090939,0.0009471528,0.0002847277,0.002017994,0.000485656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007751154,"about_ca_system_score_gemma":0.0007389875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007771834,"about_ca_topic_score_gemma":0.001696564,"domain_scores_codex":[0.9994627,0.0002140391,0.00005317833,0.00009096288,0.00009995092,0.00007920693],"domain_scores_gemma":[0.9993306,0.0001467292,0.0002274471,0.00008641987,0.00006471427,0.0001440967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5496983,0.0110634,0.03396036,0.002189307,0.01152797,0.0004722969,0.0002877162,0.005808958,0.06566449,0.0003638025,0.007819812,0.3111437],"study_design_scores_gemma":[0.5041184,0.2263905,0.208068,0.0002353863,0.0185302,0.001902586,0.0002175563,0.005078518,0.01672552,0.0005579121,0.01797993,0.0001954383],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885553,0.006941766,0.0004120013,0.0003889483,0.0001060173,0.000247108,0.001452512,0.00009694753,0.001799365],"genre_scores_gemma":[0.9928929,0.00241827,0.0006143685,0.0004339723,0.000104938,0.0001904541,0.00230636,0.00002294579,0.00101569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002504159,"threshold_uncertainty_score":0.008704245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01983071802193114,"score_gpt":0.2446170420919442,"score_spread":0.2247863240700131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}